Overview

Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized

Status:
Active, not recruiting

Trial end date:
2021-01-29

Target enrollment:

Participant gender:

Summary

Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-T Eye drops 0.15% and ALPHAGAN-P Eye drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial

Phase:

Phase 4

Details

Lead Sponsor:

CHA University

Collaborator:

Hanlim Pharm. Co., Ltd.

Treatments:

Brimonidine Tartrate
Ophthalmic Solutions